Ra Capital Management, L.P. Sells 51,363 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 51,363 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $30.55, for a total transaction of $1,569,139.65. Following the transaction, the director directly owned 82,836 shares in the company, valued at $2,530,639.80. The trade was a 38.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, October 17th, Ra Capital Management, L.P. sold 260,859 shares of Vor Biopharma stock. The stock was sold at an average price of $29.39, for a total transaction of $7,666,646.01.
• On Thursday, October 16th, Ra Capital Management, L.P. sold 151,803 shares of Vor Biopharma stock. The shares were sold at an average price of $29.45, for a total transaction of $4,470,598.35.

Vor Biopharma Price Performance

NASDAQ VOR opened at $29.00 on Friday. Vor Biopharma Inc. has a 1-year low of $2.62 and a 1-year high of $65.80. The stock has a fifty day moving average of $36.55. The firm has a market capitalization of $198.77 million, a P/E ratio of -0.11 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts’ consensus estimates of ($11.40) by ($32.20).

Wall Street Analysts Forecast Growth

VOR has been the topic of a number of research reports. Wall Street Zen downgraded Vor Biopharma to a “strong sell” rating in a report on Saturday, June 28th. Robert W. Baird raised shares of Vor Biopharma from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $20.00 to $64.00 in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Stifel Nicolaus raised shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research note on Wednesday, September 24th. Finally, Zacks Research downgraded shares of Vor Biopharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $77.83.

Institutional Trading of Vor Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of VOR. OMERS ADMINISTRATION Corp bought a new stake in shares of Vor Biopharma during the 1st quarter worth $100,000. Goldman Sachs Group Inc. lifted its position in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares during the last quarter. Money Concepts Capital Corp boosted its holdings in Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after acquiring an additional 26,535 shares during the period. Jane Street Group LLC acquired a new stake in shares of Vor Biopharma in the first quarter valued at about $140,000. Finally, XTX Topco Ltd bought a new position in shares of Vor Biopharma in the second quarter worth about $66,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.